StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
INDOUS.BO$99.50+0.70%
Fair $99.50+0.0%

INDOUS.BO

Indo Us Bio-Tech Limited

Basic Materials / Agricultural InputsBSE

$99.50

+0.70 (+0.70%)

Fairly Valued+0.0%Fair Value $99.50Fund rank 26/100 · Data gapFallback financials|
SA 47/C
F-Score: 7/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 18%

FCF escenarios

weak_data · normalized FCF $-3.9M · quality 45.7/100

Data gap 26/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 15/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

47/100

C

Piotroski

7/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific commodity mid-cycle model required: targets are disabled until normalized cycle price/cost-curve/reserve data exists.
Thesis & Journal · INDOUS.BOLocal privado en este navegador · Indo Us Bio-Tech Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$2.0B

P/E

13.4x

↓

EV/EBITDA

11.2x

↑

ROE

20.7%

↑

Gross Margin

28.4%

↑

Debt/Equity

0.19

↓
52-Week Range$100
$95$205

TradingView lightweight chart

INDOUS.BO price, volumen y niveles de valoración

Último $100.45Periodo -62.6%
Fair value: $99.50

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+27.5%

FCF CAGR

—

FCF margin

0.5%

FCF / Net income

0.03x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1.04B · net income $162.7M · FCF $5.6M

2022-FY → 2025-FY

Gross margin

28.4%+2.0% pts

Operating margin

17.3%+4.0% pts

Net margin

15.7%+5.6% pts

FCF margin

0.5%+3.1% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$1.04B$1.04B$728.4M$617.4M$500.6M
Net Income$162.7M$162.7M$82.4M$72.4M$50.6M
EBITDA$190.6M$190.6M$110.0M$93.4M$69.0M
EPS8.128.124.117.514.13
Gross Margin28.4%28.4%28.3%25.9%26.4%
Operating Margin17.3%17.3%14.2%13.9%13.3%
Net Margin15.7%15.7%11.3%11.7%10.1%
Balance Sheet
Debt/Equity0.190.190.230.210.33
Cash Flow
Free Cash Flow$5.6M$5.6M$-3.9M$-13.0M$-12.6M
Returns
ROE20.7%20.7%13.1%13.3%13.1%
Valuation
P/E13.4513.45———
EV/EBITDA11.2311.23———
P/B2.542.54———
Growth & Yield
Revenue Growth42.6%42.6%18.0%23.3%—
EPS Growth97.6%97.6%-45.3%81.6%—
Dividend Yield0.2%0.2%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

2.8%

fácil

EPS terminal req.

$8.83

Spread vs growth

94.7%

5Y implied EPS CAGR

5.6%

razonable

EPS terminal req.

$10.68

Spread vs growth

91.9%

10Y implied EPS CAGR

7.8%

razonable

EPS terminal req.

$17.21

Spread vs growth

89.8%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -33.4%

Total return

-33.4%

Start / end P/E

36.8x → 12.4x

EPS bridge

4.11 → 8.12

Residual

-64.7%

EPS growth+97.6%
Multiple rerating-66.4%
Dividend+0.2%
Residual / FX / buybacks / cross-term-64.7%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.